• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PhaseBio Pharmaceuticals Inc. (Amendment)

    2/14/23 2:26:56 PM ET
    $PHAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAS alert in real time by email
    SC 13G/A 1 d9942235_13g-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    PhaseBio Pharmaceuticals, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

    717224109
    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     


    CUSIP No.
    717224109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Partners Management LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,040,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,040,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,040,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.1%1  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

    ____________________

    1 The percentage of ownership based on 49,858,116 shares of Common Stock of the Issuer outstanding as of August 8, 2022, as reported on the Issuer’s Form 10-Q filed on August 12, 2022.

     

     
     

     


    CUSIP No.
    717224109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Partners Management (GP) LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,040,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,040,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,040,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.1%2  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    ____________________

    2 The percentage of ownership based on 49,858,116 shares of Common Stock of the Issuer outstanding as of August 8, 2022, as reported on the Issuer’s Form 10-Q filed on August 12, 2022.

     

     

     
     

     


    CUSIP No.
    717224109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Capital Partners Fund (GP) LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,040,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,040,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,040,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.1%3  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

     

    ____________________

    3 The percentage of ownership based on 49,858,116 shares of Common Stock of the Issuer outstanding as of August 8, 2022, as reported on the Issuer’s Form 10-Q filed on August 12, 2022.

     

     

     
     

     


    CUSIP No.
    717224109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Capital Partners (GP) LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,040,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,040,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,040,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.1%4  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    ____________________

    4 The percentage of ownership based on 49,858,116 shares of Common Stock of the Issuer outstanding as of August 8, 2022, as reported on the Issuer’s Form 10-Q filed on August 12, 2022.

     

     

     
     

     


    CUSIP No.
    717224109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Master Fund LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,563,634  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,563,634  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,563,634  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      3.1%5  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

     

    ____________________

    5 The percentage of ownership based on 49,858,116 shares of Common Stock of the Issuer outstanding as of August 8, 2022, as reported on the Issuer’s Form 10-Q filed on August 12, 2022.

     

     

     

     

     


    CUSIP No
    717224109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      David Witzke  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,040,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,040,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,040,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.1%6  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    ____________________

    6 The percentage of ownership based on 49,858,116 shares of Common Stock of the Issuer outstanding as of August 8, 2022, as reported on the Issuer’s Form 10-Q filed on August 12, 2022.

     

     

     
     

     


    CUSIP No
    717224109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Michael Gregory  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,040,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,040,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,040,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.1%7  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    ____________________

    7 The percentage of ownership based on 49,858,116 shares of Common Stock of the Issuer outstanding as of August 8, 2022, as reported on the Issuer’s Form 10-Q filed on August 12, 2022.

     

     

     
     

     

    Item 1. (a). Name of Issuer:  
           
        PhaseBio Pharmaceuticals, Inc.  

     

      (b). Address of issuer's principal executive offices:  
           
       

    1 Great Valley Parkways, Suite 30

    Malvern, Pennsylvania 19355

    United States of America

     

     

    Item 2. (a). Name of person filing:  
           
       

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

    David Witzke

    Michael Gregory

     

     

      (b). Address or principal business office or, if none, residence:  
           
       

    Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Partners Management (GP) LLC

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Capital Partners Fund (GP) LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Capital Partners (GP) LLC

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Master Fund LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    David Witzke

    c/o Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Michael Gregory

    c/o Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

     

     
     

     

      (c). Citizenship:  
           
       

    Avidity Partners Management LP– Delaware

    Avidity Partners Management (GP) LLC – Delaware

    Avidity Capital Partners Fund (GP) LP – Delaware

    Avidity Capital Partners (GP) LLC – Delaware

    Avidity Master Fund LP – Cayman Islands

    David Witzke – United States of America

    Michael Gregory – United States of America

     

     

      (d).   Title of class of securities:  
           
       

    Common Stock, par value $0.001 per share

     

     

     

      (e). CUSIP No.:  
           
        717224109  

     

    Item 3.   If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

      (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [_] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

      (k)   [_] Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     
     

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
       

    Avidity Partners Management LP: 2,040,000

    Avidity Partners Management (GP) LLC: 2,040,000

    Avidity Capital Partners Fund (GP) LP: 2,040,000

    Avidity Capital Partners (GP) LLC: 2,040,000

    Avidity Master Fund LP: 1,563,634

    David Witzke: 2,040,000

    Michael Gregory: 2,040,000

     

      (b) Percent of class:
         
       

    Avidity Partners Management LP: 4.1%

    Avidity Partners Management (GP) LLC: 4.1%

    Avidity Capital Partners Fund (GP) LP: 4.1%

    Avidity Capital Partners (GP) LLC: 4.1%

    Avidity Master Fund LP: 3.1%

    David Witzke: 4.1%

    Michael Gregory: 4.1%

     

      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    David Witzke: 0

    Michael Gregory: 0

     

    ,

             
        (ii)   Shared power to vote or to direct the vote

    Avidity Partners Management LP: 2,040,000

    Avidity Partners Management (GP) LLC: 2,040,000

    Avidity Capital Partners Fund (GP) LP: 2,040,000

    Avidity Capital Partners (GP) LLC: 2,040,000

    Avidity Master Fund LP: 1,563,634

    David Witzke: 2,040,000

    Michael Gregory: 2,040,000

    ,
             
        (iii) Sole power to dispose or to direct the disposition of

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    David Witzke: 0

    Michael Gregory: 0

     

    ,

             
        (iv)   Shared power to dispose or to direct the disposition of

    Avidity Partners Management LP: 2,040,000

    Avidity Partners Management (GP) LLC: 2,040,000

    Avidity Capital Partners Fund (GP) LP: 2,040,000

    Avidity Capital Partners (GP) LLC: 2,040,000

    Avidity Master Fund LP: 1,563,634

    David Witzke: 2,040,000

    Michael Gregory: 2,040,000

     

    .

             

     

     
     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

      N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A

     

    Item 8. Identification and Classification of Members of the Group.

     

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       
    Item 9. Notice of Dissolution of Group.

     

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

     

    February 14, 2023

      (Date)
       
     

    David Witzke

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

     

      By: /s/ David Witzke
      David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))
       
     

    Michael Gregory

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

     

      By: /s/Michael Gregory
      Michael Gregory, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit 1

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of PhaseBio Pharmaceuticals, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing

     The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

     

    IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of February 14, 2023.

     

    David Witzke

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

     

      By: /s/ David Witzke
      David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))
       
     

    Michael Gregory

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

     

      By: /s/Michael Gregory
      Michael Gregory, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))
    Get the next $PHAS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHAS

    DatePrice TargetRatingAnalyst
    9/28/2022$15.00 → $1.00Buy → Hold
    Stifel
    10/13/2021$15.00Buy
    Stifel
    More analyst ratings

    $PHAS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code

      Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. As part of the case, PhaseBio also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures, if approved by the court, would require interested parties to submit binding offers

      10/24/22 8:00:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

      PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities. "The second quarter of 2022 marked a period of continued progress for PhaseBio," said Jonathan Mow, Chief Executive Officer of PhaseBio Pharmaceuticals. "Following a successful meeting with the U.S. Food and Drug Administration (FDA) during our pre-biologics license application (pre-BLA) meeting earlier this year and as previously disclosed, we have been focused on clinical developmen

      8/12/22 8:30:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

      Held successful Type B pre-biologics license application (BLA) meeting with U.S. FDA for future submission of BLA for bentracimab BLA submission for bentracimab is planned for early in the fourth quarter of 2022 and PhaseBio is preparing for commercialization in U.S., if approved Presented positive results from Phase 2b trial for bentracimab at ACC.22 Completed the Process Performance Qualification (PPQ) campaign demonstrating commercial scale manufacturing ability for bentracimab PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financia

      5/16/22 6:00:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    SEC Filings

    See more
    • PhaseBio Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)

      11/29/23 4:55:08 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by PhaseBio Pharmaceuticals Inc.

      NT 10-Q - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)

      11/15/23 4:17:16 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

      8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)

      10/3/23 7:17:19 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    Financials

    Live finance-specific insights

    See more
    • PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab

      PhaseBio recently received formal written minutes from the FDA following its Pre-BLA Meeting held in early April and is expecting to submit its Biologics License Application (BLA) by early in the fourth quarter of 2022 The FDA indicated willingness to accept a BLA with data from 25-30 uncontrolled bleeding patients, in addition to surgical patients enrolled to date, to potentially support a label that includes both surgical and uncontrolled bleeding indications To date, PhaseBio has enrolled 35 uncontrolled bleeding patients and has completed enrolling surgical patients in the Phase 3 REVERSE-IT trial Conference call and webcast today at 8:30 a.m. ET PhaseBio Pharmaceuticals, Inc. (NASD

      5/16/22 6:00:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding

      Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations Co-primary endpoint of clinical hemostasis achieved in greater than 90% of patients Bentracimab appeared well tolerated with no drug-related serious adverse events Results presented today in Late-Breaking Science Session at the American Heart Association's 2021 Scientific Sessions and accepted for publication in NEJM Evidence, a new digital journal from the NEJM (New England Journal of Medicine) Group Investor webcast scheduled for today at 12:30 p.m. ET PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHA

      11/15/21 11:31:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting

      Prespecified interim analysis of pivotal REVERSE-IT Phase 3 trial to be presented during late-breaking science session on November 15th at the American Heart Association's Scientific Sessions 2021 Guest speakers include Deepak L. Bhatt, M.D., MPH; Charles Pollack, M.D.; and Philippe Gabriel Steg, M.D. Video webcast to be held on November 15, 2021, at 12:30 p.m. ET (9:30 a.m. PT) PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it will host an investor call on November 15, 2021, at 12:30 p.m. ET (9:30 a.m. PT) to discuss the results

      11/10/21 8:01:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PhaseBio Pharmaceuticals downgraded by Stifel with a new price target

      Stifel downgraded PhaseBio Pharmaceuticals from Buy to Hold and set a new price target of $1.00 from $15.00 previously

      9/28/22 12:51:14 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel resumed coverage on PhaseBio Pharmaceuticals with a new price target

      Stifel resumed coverage of PhaseBio Pharmaceuticals with a rating of Buy and set a new price target of $15.00

      10/13/21 7:53:54 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on PhaseBio Pharmaceuticals with a new price target

      Needham reiterated coverage of PhaseBio Pharmaceuticals with a rating of Buy and set a new price target of $15.00 from $16.00 previously

      6/17/21 11:20:30 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Van Den Broek Richard

      4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)

      5/19/23 4:18:54 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Thorp Clay

      4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)

      5/19/23 4:18:34 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Humphries William D.

      4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)

      5/19/23 4:18:07 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by PhaseBio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)

      2/14/23 4:45:46 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PhaseBio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)

      2/14/23 3:01:05 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PhaseBio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)

      2/14/23 2:26:56 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAS
    Leadership Updates

    Live Leadership Updates

    See more
    • PhaseBio Names Jonathan Birchall as Chief Commercial Officer

      PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer. "Jonathan brings to PhaseBio deep commercial expertise in the critical-care setting, which he gained through his leadership of the thrombolytics franchise at Genentech," said Jonathan P. Mow, Chief Executive Officer of PhaseBio. "With his background and track record of success, Jonathan has the experience necessary to lead our commercial organization and joins us at a pivotal time in PhaseBio's evolution as we begin prepar

      11/18/21 4:01:00 PM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PhaseBio Appoints William D. Humphries to Board of Directors

      PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its board of directors. Additionally, Justin Klein, M.D., J.D., is stepping down from his role as director, effective immediately. "Bill's deep commercial expertise gained through his leadership roles at numerous specialty pharmaceutical companies will be an invaluable addition to our already robust board of directors," said Jonathan P. Mow, Chief Executive Officer of PhaseBio. "Bill joins us at an exciting and pivotal time in PhaseBio's growth, as

      9/15/21 8:00:00 AM ET
      $PHAS
      Biotechnology: Pharmaceutical Preparations
      Health Care